Sign in or create an account to add this stock to your watchlist.
About Progenics Pharmaceuticals (NASDAQ:PGNX)
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:PGNX
CUSIP74318710
Phone646-975-2500
Debt
Debt-to-Equity Ratio0.74
Current Ratio6.44
Quick Ratio6.44
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.70 million
Price / Sales47.38
Cash FlowN/A
Price / CashN/A
Book Value$0.82 per share
Price / Book9.17
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-51,010,000.00
Net Margins-383.39%
Return on Equity-92.43%
Return on Assets-39.20%
Miscellaneous
Employees64
Outstanding Shares73,720,000
Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) released its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.04. The biotechnology company had revenue of $3.19 million for the quarter, compared to the consensus estimate of $4.10 million. Progenics Pharmaceuticals had a negative return on equity of 92.43% and a negative net margin of 383.39%. View Progenics Pharmaceuticals' Earnings History.
When is Progenics Pharmaceuticals' next earnings date?
What price target have analysts set for PGNX?
4 Wall Street analysts have issued 1 year price objectives for Progenics Pharmaceuticals' shares. Their predictions range from $12.00 to $15.00. On average, they expect Progenics Pharmaceuticals' share price to reach $13.75 in the next year. View Analyst Ratings for Progenics Pharmaceuticals.
What are Wall Street analysts saying about Progenics Pharmaceuticals stock?
Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating and 12-month PT of $15 on the shares of PGNX. Although we like the rare disease opportunity for AZEDRA (PDUFA 7/30), we also like the PSMA-targeted pipeline for prostate cancer. Moreover, what we have come to appreciate in the PGNX story is the optionality of the pipeline, which extends to the potential for out-licensing, financing and clinical development." (5/20/2018)
- 2. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (5/11/2018)
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Corcept Therapeutics (CORT), Insmed (INSM), Xencor (XNCR), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Spectrum Pharmaceuticals (SPPI), Puma Biotechnology (PBYI), AnaptysBio (ANAB), Akcea Therapeutics (AKCA), Aimmune Therapeutics (AIMT), Enanta Pharmaceuticals (ENTA), Phibro Animal Health (PAHC), Prestige Brands (PBH) and Akorn (AKRX).
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Mr. Mark R. Baker, CEO & Director (Age 63)
- Mr. Patrick Fabbio, Sr. VP, CFO & Principal Accounting Officer (Age 50)
- Dr. Vivien Wong, Exec. VP of Devel. (Age 61)
- Mr. Jeffrey D. Summer, Sr. VP of Digital Technology (Age 58)
- Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 45)
Has Progenics Pharmaceuticals been receiving favorable news coverage?
News coverage about PGNX stock has been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of 0.11 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Progenics Pharmaceuticals' major shareholders?
Progenics Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.55%), Eagle Asset Management Inc. (6.06%), Carillon Tower Advisers Inc. (5.36%), Pinnacle Associates Ltd. (2.85%), Summit Trail Advisors LLC (0.55%) and Schwab Charles Investment Management Inc. (0.49%). View Institutional Ownership Trends for Progenics Pharmaceuticals.
Which institutional investors are selling Progenics Pharmaceuticals stock?
PGNX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Wells Fargo & Company MN, American International Group Inc., BKS Advisors LLC, Teacher Retirement System of Texas and BlackRock Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals.
Which institutional investors are buying Progenics Pharmaceuticals stock?
PGNX stock was purchased by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Eagle Asset Management Inc., Carillon Tower Advisers Inc., JPMorgan Chase & Co., UBS Group AG, A.R.T. Advisors LLC, Bayesian Capital Management LP and Jane Street Group LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.
How do I buy shares of Progenics Pharmaceuticals?
Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $7.52.
How big of a company is Progenics Pharmaceuticals?
Progenics Pharmaceuticals has a market capitalization of $553.63 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.
How can I contact Progenics Pharmaceuticals?
Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]
MarketBeat Community Rating for Progenics Pharmaceuticals (PGNX)
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Progenics Pharmaceuticals (NASDAQ:PGNX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Progenics Pharmaceuticals in the last 12 months. Their average twelve-month price target is $13.75, suggesting that the stock has a possible upside of 82.85%. The high price target for PGNX is $15.00 and the low price target for PGNX is $12.00. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.25 | 3.25 | 3.25 | 3.20 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $13.75 | $13.75 | $13.75 | $13.20 |
| Price Target Upside: | 82.85% upside | 64.47% upside | 123.58% upside | 113.25% upside |
Progenics Pharmaceuticals (NASDAQ:PGNX) Consensus Price Target History
Progenics Pharmaceuticals (NASDAQ:PGNX) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Progenics Pharmaceuticals (NASDAQ:PGNX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 86.46%
Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/15/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 602,600 | $9.66 | $5,821,116.00 | |  |
| 2/9/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 351,300 | $9.71 | $3,411,123.00 | | |
| 6/11/2015 | Robert J Israel | EVP | Sell | 2,000 | $6.83 | $13,660.00 | | |
| 3/13/2015 | Robert J Israel | EVP | Sell | 3,000 | $7.00 | $21,000.00 | | |
| 3/11/2015 | Robert J Israel | EVP | Sell | 2,000 | $6.83 | $13,660.00 | | |
| 3/3/2015 | Robert J Israel | EVP | Sell | 5,000 | $6.49 | $32,450.00 | | |
| 1/12/2015 | Robert J Israel | EVP | Sell | 2,000 | $7.06 | $14,120.00 | | |
| 12/11/2014 | Robert J Israel | EVP | Sell | 3,000 | $7.07 | $21,210.00 | | |
| 11/21/2014 | Robert J Israel | EVP | Sell | 9,000 | $7.00 | $63,000.00 | | |
| 11/13/2014 | Robert J Israel | EVP | Sell | 10,000 | $6.83 | $68,300.00 | | |
| 11/11/2014 | Robert J Israel | EVP | Sell | 5,000 | $6.53 | $32,650.00 | | |
| 7/21/2014 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 1,625,436 | $4.60 | $7,477,005.60 | | |
| 7/18/2014 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 388,200 | $4.73 | $1,836,186.00 | | |
| 7/17/2014 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 436,884 | $4.48 | $1,957,240.32 | | |
| 7/16/2014 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 411,693 | $4.48 | $1,844,384.64 | | |
| 7/18/2013 | Robert J Israel | VP | Sell | 5,000 | $6.33 | $31,650.00 | | |
| 2/27/2013 | Mark Robert Baker | CEO | Buy | 1,262 | $2.72 | $3,432.64 | | |
| 1/22/2013 | Mark Robert Baker | CEO | Buy | 1,215 | $2.82 | $3,426.30 | | |
| 12/26/2012 | Mark Robert Baker | CEO | Buy | 1,142 | $3.01 | $3,437.42 | | |
| 11/28/2012 | Mark Robert Baker | CEO | Buy | 1,607 | $2.13 | $3,422.91 | | |
| 11/19/2012 | Mark Robert Baker | CEO | Buy | 11,800 | $1.96 | $23,128.00 | | |
| 11/16/2012 | Mark Robert Baker | CEO | Buy | 49,793 | $1.82 | $90,623.26 | | |
| 11/15/2012 | Mark Robert Baker | CEO | Buy | 48,833 | $1.69 | $82,527.77 | | |
| 10/24/2012 | Mark Robert Baker | CEO | Buy | 1,162 | $2.96 | $3,439.52 | | |
| 9/26/2012 | Mark Robert Baker | CEO | Buy | 1,036 | $3.32 | $3,439.52 | | |
(Data available from 1/1/2013 forward)
Progenics Pharmaceuticals (NASDAQ PGNX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Traders Purchase High Volume of Call Options on Progenics Pharmaceuticals (PGNX)
www.americanbankingnews.com - May 25 at 6:44 AM |
| Progenics Pharmaceuticals, Inc. (PGNX) to Post FY2018 Earnings of ($0.63) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - May 24 at 8:22 AM |
 | Progenics' aBSI shows prognostic value in late-stage study
seekingalpha.com - May 22 at 4:42 PM |
 | Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform
finance.yahoo.com - May 22 at 8:56 AM |
| Progenics Pharmaceuticals: Elucidating The Upcoming Regulatory Binary For Azedra
seekingalpha.com - May 21 at 9:19 AM |
| Progenics Pharmaceuticals (PGNX) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 20 at 9:30 PM |
 | Global Prostate Cancer Therapeutics Strategic Business Report Analysis 2015-2018 Forecast to 2022
www.prnewswire.com - May 18 at 4:43 PM |
| Progenics Pharmaceuticals (PGNX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 14 at 5:58 AM |
| Q2 2018 EPS Estimates for Progenics Pharmaceuticals (PGNX) Increased by Analyst
www.americanbankingnews.com - May 14 at 1:58 AM |
 | BRIEF-Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating ...
www.reuters.com - May 13 at 9:37 AM |
| Progenics Pharmaceuticals (PGNX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 11 at 12:49 PM |
| Progenics Pharmaceuticals (PGNX) Forecasted to Post FY2021 Earnings of $0.63 Per Share
www.americanbankingnews.com - May 11 at 11:47 AM |
| Progenics Earnings: Get Ready For A Massive Move
seekingalpha.com - May 10 at 9:28 AM |
| Edited Transcript of PGNX earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 9:28 AM |
| Progenics Pharmaceuticals Sees Unusually Large Options Volume (PGNX)
www.americanbankingnews.com - May 10 at 7:40 AM |
| Progenics Pharmaceuticals' (PGNX) CEO Mark Baker on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:42 PM |
| Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 9 at 3:17 PM |
| Progenics Pharmaceuticals (PGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 9 at 2:25 PM |
 | Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
globenewswire.com - May 9 at 9:15 AM |
| Progenics Pharmaceuticals beats by $0.02, misses on revenue
seekingalpha.com - May 9 at 9:15 AM |
| Progenics revenues up 39%; net loss improves in Q1
seekingalpha.com - May 9 at 9:15 AM |
| Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
finance.yahoo.com - May 9 at 9:15 AM |
| Progenics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:15 AM |
 | Noteworthy Tuesday Option Activity: BA, PGNX, AMBA
www.nasdaq.com - May 8 at 4:43 PM |
| New Analyst Coverage Puts Spotlight on These 4 Stocks
finance.yahoo.com - May 7 at 4:46 PM |
| Progenics Pharmaceuticals (PGNX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 7 at 11:58 AM |
 | Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection
feeds.benzinga.com - May 2 at 9:45 PM |
| The No BS Report, Week 11: Rising Tides And Sinking Ships?
seekingalpha.com - May 1 at 9:07 AM |
| Research Report Identifies Cracker Barrel Old Country Store, Enova International, Natera, Inovalon, UMH Properties ...
globenewswire.com - May 1 at 9:07 AM |
| BidaskClub Lowers Progenics Pharmaceuticals (PGNX) to Hold
www.americanbankingnews.com - May 1 at 8:12 AM |
| Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9
finance.yahoo.com - April 26 at 9:11 AM |
| Progenics Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 26 at 9:11 AM |
| Progenics Pharmaceuticals (PGNX) to Release Earnings on Wednesday
www.americanbankingnews.com - April 25 at 7:33 AM |
| Progenics Pharmaceuticals (PGNX) Downgraded by BidaskClub
www.americanbankingnews.com - April 21 at 7:24 AM |
| Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 19 at 12:49 PM |
| Progenics Pharmaceuticals, Inc. (PGNX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 19 at 5:56 AM |
| Cantor Fitzgerald Begins Coverage on Progenics Pharmaceuticals (PGNX)
www.americanbankingnews.com - April 18 at 8:34 PM |
| Progenics Pharmaceuticals (PGNX) PT Set at $15.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 11 at 7:19 PM |
| Progenics Talks Commercialization, Pipeline, And Milestones
seekingalpha.com - April 10 at 9:29 AM |
| Progenics Pharmaceuticals' (PGNX) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - April 9 at 10:55 PM |
| Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 7 at 7:02 AM |
| Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM |
| Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.'s FY2018 Earnings (PGNX)
www.americanbankingnews.com - April 6 at 7:24 AM |
| Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 11:52 AM |
| Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - March 31 at 10:54 AM |
| Progenics Pharmaceuticals (PGNX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 6:15 PM |
| Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 28 at 12:24 PM |
| Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 25 at 5:32 AM |
| 3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News
seekingalpha.com - March 24 at 5:12 PM |
| Progenics Pharmaceuticals (PGNX) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 24 at 3:52 PM |
Progenics Pharmaceuticals (NASDAQ:PGNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Progenics Pharmaceuticals (NASDAQ:PGNX) Income Statement, Balance Sheet and Cash Flow Statement
Progenics Pharmaceuticals (NASDAQ PGNX) Stock Chart for Saturday, May, 26, 2018
Loading chart…
